28bio

United States · Biotech

28bio develops human neural tissue models and services that help drug developers assess neurological safety and efficacy.

Product and customers

28bio helps drug developers study how compounds affect human neural tissue. Its CNS-3D brain organoids and peripheral nervous system services support research into toxicity and therapeutic effects.

The company offers models for areas including neuroinflammation, myelination and Alzheimer’s disease. Its products and services measure neural activity to help researchers assess drug effects before and alongside clinical development.

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Equity offering$8.5MParticipants not disclosed
Sources28bio.com ↗28bio.com ↗